271 related articles for article (PubMed ID: 8252739)
1. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
Földes J; Tarján G; Szathmari M; Varga F; Krasznai I; Horvath C
Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
[TBL] [Abstract][Full Text] [Related]
2. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Lehmke J; Bogner U; Felsenberg D; Peters H; Schleusener H
Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
[TBL] [Abstract][Full Text] [Related]
3. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause.
Jódar E; Muñoz-Torres M; Escobar-Jiménez F; Quesada-Charneco M; Lund del Castillo JD
Clin Endocrinol (Oxf); 1997 Sep; 47(3):279-85. PubMed ID: 9373448
[TBL] [Abstract][Full Text] [Related]
4. Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism.
Földes J; Lakatos P; Zsadányi J; Horváth C
Eur J Endocrinol; 1997 Mar; 136(3):277-81. PubMed ID: 9100552
[TBL] [Abstract][Full Text] [Related]
5. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women.
Gürlek A; Gedik O
Thyroid; 1999 Jun; 9(6):539-43. PubMed ID: 10411115
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in postmenopausal women treated with L-thyroxine.
Adlin EV; Maurer AH; Marks AD; Channick BJ
Am J Med; 1991 Mar; 90(3):360-6. PubMed ID: 2003518
[TBL] [Abstract][Full Text] [Related]
7. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
8. Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover.
Jódar Gimeno E; Muñoz-Torres M; Escobar-Jiménez F; Quesada Charneco M; Luna del Castillo JD; Oleà N
Calcif Tissue Int; 1997 Nov; 61(5):370-6. PubMed ID: 9351877
[TBL] [Abstract][Full Text] [Related]
9. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism.
Tauchmanovà L; Nuzzo V; Del Puente A; Fonderico F; Esposito-Del Puente A; Padulla S; Rossi A; Bifulco G; Lupoli G; Lombardi G
Maturitas; 2004 Jul; 48(3):299-306. PubMed ID: 15207896
[TBL] [Abstract][Full Text] [Related]
10. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
12. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.
Faber J; Jensen IW; Petersen L; Nygaard B; Hegedüs L; Siersbaek-Nielsen K
Clin Endocrinol (Oxf); 1998 Mar; 48(3):285-90. PubMed ID: 9578817
[TBL] [Abstract][Full Text] [Related]
13. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
14. Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.
Serraclara A; Jódar E; Sarabia F; Hawkins F
J Clin Densitom; 2001; 4(3):249-55. PubMed ID: 11740067
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density in rural Thai adults living in Khon Kaen province.
Pongchaiyakul C; Rojroongwasinkul N; Chotmongkol R; Kosulwat V; Charoenkiatkul S; Rajatanavin R
J Med Assoc Thai; 2002 Feb; 85(2):235-44. PubMed ID: 12081125
[TBL] [Abstract][Full Text] [Related]
16. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.
Mudde AH; Houben AJ; Nieuwenhuijzen Kruseman AC
Clin Endocrinol (Oxf); 1994 Oct; 41(4):421-4. PubMed ID: 7955452
[TBL] [Abstract][Full Text] [Related]
17. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
18. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
19. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
20. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Kung AW; Lorentz T; Tam SC
Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
